Myocardial Structure, Function, and Quality of Life
heart failure, Cardiomyopathy, HFpEF, hypertrophy
CARDIOMYOPATHY, HYPERTROPHY, REGRESSION, HEART FAILURE, TYPE 2 DIABETES
Although exploratory and not sufficiently powered, we observed changes indicating reduced hypertrophy and regression of cell volume in the HFrEF cohort. These findings are in keeping with a recent meta-analysis of imaging trials assessing empagliflozin or dapagliflozin in patients with type 2 diabetes and/or HFrEF.Finally, patients in both treatment groups (empagliflozin and placebo) and both cohorts (HFrEF and HFpEF) showed a trend toward improvements in quality of life (Kansas City Cardiomyopathy Questionnaire), although these were numerically greater in the empagliflozin arm (Figure 
Changes in Kansas City Cardiomyopathy Questionnaire (baseline to week 12).
Boxplot showing unadjusted mean change from baseline to week 12 in the overall summary score (OSS) and clinical summary score (CSS) of the Kansas City Cardiomyopathy Questionnaire for the placebo (blue) and empagliflozin (red) groups in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Whiskers indicate SD.